A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC
20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 36 months.
Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer
BIOLOGICAL: Autologous Tumor Infiltrating Lymphocytes
Adverse Events, Incidence of adverse events associated with GC101 TIL retransfusion, Up to Day 28|Objective Response Rate, Proportion of subjects in total cases in complete or partial response (RECIST v1.1 criteria), 18 weeks
Adverse Events, Incidence of adverse events associated with GC101 TIL retransfusion, Maximum 360 days|Objective Response Rate, Proportion of subjects in total cases in complete or partial response (RECIST v1.1 criteria) during the study, Maximum 36 months|Best overall response, Optimal efficacy recorded from the start of treatment until disease progression or relapse (RECIST v1.1 and iRECIST), Maximum 36 months|Disease Control Rate, Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST, Maximum 36 months|Progression-Free Survival, Evaluate the efficacy endpoints of PFS by the investigator with RECIST v1.1 and iRECIST, Maximum 36 months|Duration of Response, Evaluate the efficacy endpoints of DOR by the investigator with RECIST v1.1 and iRECIST, Maximum 36 months|overall survival, Evaluate the efficacy endpoints of OS, Maximum 36 months
20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 36 months.